Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Izzy who wrote (4265)	5/7/1998 2:18:00 PM
From: Bhag Karamchandani	Read Replies (1) \| Respond to of 6136

'Why would the "insiders" want to buy more shares? ' If you accept that AGPH is a stable revenue producing commercial entity with a steady growth rate exceeding earnings multiples, then, as many on this thread have argued, AGPH is fundamentally undervalued. What better than for AGPH insiders to buy their company stock for the same reasons that dozens of insiders of other comapanies do; they see value and are confident about the future of their company. Just see the spate of insider buys( and sells)reported weekly in Barron's. You don't have to necessarily accept this argument if you don't wish to.